Sanofi Completes Acquisition of Protein Sciences

on Aug 29, 2017 in news

8/29/17

 

Yesterday Sanofi announced that the acquisition of biotech firm Protein Sciences has been completed.  Sanofi Pasteur has a broad influenza vaccine portfolio and now has an even broader one with the addition of Flublok.  Flublok is the only recombinant protein based influenza vaccine approved by the FDA.  This is a non egg based influenza vaccine and an opportunity to research these manufacturing technologies. Read more.